Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms

Completed · Phase 4 · Has a placebo group

Conditions studied: Abdominal Aortic Aneurysm

In brief

The purpose of this study is to determine if telmisartan is effective in slowing the progression of abdominal aortic aneurysms and reducing circulating concentrations of Abdominal Aortic Aneurysms (AAA) biomarkers.

Key facts

Study ID

NCT01683084

Run by

Palo Alto Veterans Institute for Research

People needed

22

Starts

2012-09-19

Expected to finish

2018-11-10

Last updated by the study team

2020-05-26

Who can join

Age: 50 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 50-85 years of age and able to provide written informed consent
• AAA measuring a maximum diameter of 3.5-4.9 cm on CTA or ultrasound
• Stable medication regime for the last six months
• No current indication for AAA repair according to the treating physician or expectation that this will be revised within the next year
• High likelihood of compliance with treatment over 24 months

You may not qualify if…

• Renal impairment (i.e. creatinine >1.5x upper limit of normal [ULN])
• Known significant renal stenosis (>70%) of one or both renal arteries
• Chronic liver disease (i.e. cirrhosis or hepatitis) or abnormal liver function (i.e. ALT 1.5xULN)
• Electrolyte imbalance
• Active gout
• Current or planned usage of an AT1 blocker or ACE inhibitor
• Previous abdominal aortic surgery
• Currently pregnant or intend to become pregnant

Where it is running

• VA Palo Alto Health Care System — Palo Alto, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.